{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"324.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"title":"Crizotinib Ctrough: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40","value":"320.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Crizotinib Ctrough: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"308.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"title":"Crizotinib Ctrough: Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"98.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"title":"PF-06260182 Ctrough: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49","value":"99.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"title":"PF-06260182 Ctrough: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55","value":"92.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"PF-06260182 Ctrough: Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"}],"units":"Participants"}],"description":"Ctrough is the concentration prior to study drug administration on Day 1 of Cycle 2 onwards. PF-06260182 is the metabolite of Crizotinib.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic concentration population included all participants in the safety analysis population who had at least 1 plasma concentration of crizotinib or its metabolite.N=participants evaluable for this measure.Number of participants analyzed(n)=participants evaluable at specified time points.This analysis was performed in crizotinib arm only.","reportingStatus":"POSTED","timeFrame":"Predose at Day 1 of Cycle 2, 3 and 5","title":"Plasma Predose Concentration (Ctrough) of Crizotinib and Its Metabolite PF-06260182","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter"}